These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 1100951)

  • 1. Rifampicin: the investigation of a bactericidal antileprosy drug.
    Rees RJ
    Lepr Rev; 1975 Jun; 46(2 Suppl):121-4. PubMed ID: 1100951
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and bacteriological effects of rifampicin in combination with L73A in leprosy: observation for six months.
    Innami S; Leguizamón OR; Alvarenga AE
    Lepr Rev; 1975 Jun; 46(2 Suppl):169-72. PubMed ID: 1100957
    [No Abstract]   [Full Text] [Related]  

  • 3. Screening of drugs for activity against Mycobacterium leprae.
    Baohong J; Matsuo Y; Colston MJ
    Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4 Suppl):836-42. PubMed ID: 3325576
    [No Abstract]   [Full Text] [Related]  

  • 4. Multidrug resistant Mycobacterium leprae from patients with leprosy.
    Maeda S; Matsuoka M; Nakata N; Kai M; Maeda Y; Hashimoto K; Kimura H; Kobayashi K; Kashiwabara Y
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3635-9. PubMed ID: 11709358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo effects of N-methyl-3,5-dichloro-benzylamine hydrochloride on Mycobacterium leprae.
    Dhople AM; Strong LC; Meindl W; Schoenenberger H; Gardner GD
    Arzneimittelforschung; 1991 Mar; 41(3):253-6. PubMed ID: 1867663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activity of rifabutin against Mycobacterium leprae.
    Yoder LJ; Jacobson RR; Hastings RC
    Lepr Rev; 1991 Sep; 62(3):280-7. PubMed ID: 1665534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment failure in leprosy.
    Levy L
    Int J Lepr Other Mycobact Dis; 1976; 44(1-2):177-82. PubMed ID: 776854
    [No Abstract]   [Full Text] [Related]  

  • 8. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
    Matsuoka M; Kashiwabara Y; Namisato M
    Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental and clinical studies on rifampicin in treatment of leprosy.
    Rees RJ; Pearson JM; Waters MF
    Br Med J; 1970 Jan; 1(5688):89-92. PubMed ID: 4903972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice.
    Consigny S; Bentoucha A; Bonnafous P; Grosset J; Ji B
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2919-21. PubMed ID: 10991891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of sulphone resistant leprosy--a review of sixty one cases.
    Seshadri PS; Ravi NT
    Lepr India; 1982 Oct; 54(4):639-47. PubMed ID: 6191123
    [No Abstract]   [Full Text] [Related]  

  • 12. [How should leprosy be treated?].
    Mahé A
    Ann Dermatol Venereol; 1998 Dec; 125(12):881-3. PubMed ID: 9922859
    [No Abstract]   [Full Text] [Related]  

  • 13. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
    Dhople AM; Ibanez MA
    Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose treatment for paucibacillary leprosy; feasibility of long-term follow up.
    Ganapati R; Revankar CR; Pai VV; Kingsley S
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):308-9. PubMed ID: 10575413
    [No Abstract]   [Full Text] [Related]  

  • 15. [New WHO recommendations for the treatment of leprosy].
    Acta Leprol; 1997; 10(4):189. PubMed ID: 9527754
    [No Abstract]   [Full Text] [Related]  

  • 16. Structural Implications of Mutations Conferring Rifampin Resistance in Mycobacterium leprae.
    Vedithi SC; Malhotra S; Das M; Daniel S; Kishore N; George A; Arumugam S; Rajan L; Ebenezer M; Ascher DB; Arnold E; Blundell TL
    Sci Rep; 2018 Mar; 8(1):5016. PubMed ID: 29567948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapsone Resistance in Leprosy Patients Originally from American Samoa, United States, 2010-2012.
    Williams DL; Araujo S; Stryjewska BM; Scollard D
    Emerg Infect Dis; 2018 Aug; 24(8):1584-1585. PubMed ID: 30016255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Committee 4: workshop on experimental chemotherapy of leprosy.
    Int J Lepr Other Mycobact Dis; 1979 Jun; 47(2 Suppl):297-303. PubMed ID: 378876
    [No Abstract]   [Full Text] [Related]  

  • 19. Single-dose treatment for paucibacillary leprosy; clinical problems and management.
    Pai VV; Bulchand HO; Revankar CR; Ganapati R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):310-2. PubMed ID: 10575414
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug resistance in leprosy: lessons from past and future perspective.
    Gupta UD; Katoch VM
    Indian J Lepr; 1999; 71(4):451-63. PubMed ID: 10804973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.